Clinical Trial

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Name: Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus — clinical trial record (NCT06913023)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SPOT-DM

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Trial Details

NCT Number	NCT06913023
Lead Sponsor	University Health Network, Toronto
Conditions	Kidney Transplant Recipient
Enrollment	74 participants
Start Date	2026-01-05
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2025-04-06